ATXI.OQ
Latest Trade
5.94USDChange
0.01(+0.17%)Volume
1,207Today's Range
-
6.0352 Week Range
-
7.95As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 5.93 |
|---|---|
Open | 6.00 |
Volume | 1,207 |
3M AVG Volume | 0.39 |
Today's High | 6.03 |
Today's Low | 5.94 |
52 Week High | 7.95 |
52 Week Low | 4.21 |
Shares Out (MIL) | 16.66 |
Market Cap (MIL) | 100.30 |
Forward P/E | -3.76 |
Dividend (Yield %) | -- |
Avenue Therapeutics Reports Third Quarter 2019 Financial Results And Recent Corporate Highlights
Avenue Therapeutics Q2 Loss Per Share $0.43
Avenue Therapeutics Says Second Pivotal Phase 3 Trial Of IV Tramadol Achieved Primary Endpoint
Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Tramadol is also combined with acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDS) in clinical practice. During the year ending December 31, 2016, the Company had completed a pharmacokinetics (PK) study for IV Tramadol in healthy volunteers.
Industry
Biotechnology & Drugs
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 8.39 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -330.90 |
Return on Equity (TTM) | -255.08 |
By Elizabeth Dilts, Benjamin Lesser, Carl O'Donnell and Michael Erman
* AVENUE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS
* Avenue Therapeutics Inc reports third quarter 2017 financial results and recent corporate highlights
* Avenue Therapeutics reports second quarter 2017 financial results and recent corporate highlights
* Avenue Therapeutics Inc files for IPO of up to $50 million - sec filing
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.